Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based therapies and lead to significant weight loss in adults, according to ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like Ozempic ...

In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.

Novo Nordisk's amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 weeks ...

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM ...

The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved ...

Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and ...

Citing topline data from the trial, the company added that amycretin, a GLP-1 and amylin receptor agonist, indicated a safety profile in line with incretin-based drugs such as its FDA-approved ...